
SS-31 is a synthetic tetrapeptide with the sequence D-Arg–Dmt–Lys–Phe-NH2, in which Dmt is 2′,6′-dimethyltyrosine and the C-terminus is amidated[1]. Its two named residues are not interchangeable. The D-arginine supplies one of the peptide’s two cationic side chains and, in the proposed cardiolipin-binding model, one of the two electrostatic contacts with the lipid[1][2]. The dimethyltyrosine supplies the phenolic ring that structure-activity work links to antioxidant action and, together with phenylalanine, the aromatic surface that sits inside the cardiolipin acyl-chain region[1][3][4].
The Four-Residue Sequence, Position by Position
Only one residue in SS-31 is D-configured. The solid-phase synthesis reported for the peptide coupled Fmoc-D-Arg(Pbf)-OH with Fmoc-L-Lys(Boc)-OH, Fmoc-L-Phe and (S)-Fmoc-2,6-dimethyltyrosine, so the Dmt, lysine and phenylalanine residues are L[5]. The name flags one stereochemical inversion at the N-terminus, not four. The same synthesis built the chain on a Rink amide linker, which produces the C-terminal amide on cleavage[5]. The molecular weight given for the free peptide in the paper’s pharmacokinetic table is 639.79 g/mol[5].
The four positions follow an alternating aromatic–cationic motif: basic residues at positions 1 and 3, aromatic residues at 2 and 4, which is the family structure described for the SS peptides[4][1].
Two structural consequences matter for how the sequence behaves. The N-terminus is written without an acetyl or other cap, so under physiological pH conditions its free α-amino group is protonated and contributes about +1. The arginine side chain adds +1 and the lysine side chain adds +1, while the C-terminal amide carries no charge, which puts the intact peptide at roughly +3 rather than +2[1][2]. Calls to the "dicationic" or aromatic–cationic motif count the two basic side chains; they are not a statement of whole-molecule net charge. The amide cap also removes the end a carboxypeptidase would attack. Neither read source measures that protection directly: the C-terminal amide is documented as a synthetic feature, and its stability benefit is inference from peptide chemistry rather than an assay result in these papers.
D-Arginine: Charge First, Configuration Second
The arginine side chain is the peptide’s N-terminal cation. In the cardiolipin model proposed for SS-31, the two cationic moieties — arginine and lysine — interact electrostatically with the phosphate head groups of cardiolipin, while the aromatic residues, dimethyltyrosine and phenylalanine, align within the hydrophobic acyl-chain region[1]. That arrangement places the D-arginine at the membrane–water interface rather than inside the bilayer.
The D-configuration is a separate design decision from the charge. Its usual rationale is that D-amino acids are poorly recognised by peptidases, so an N-terminal D-arginine should slow aminopeptidase trimming and extend the peptide’s lifetime in tissue. The read sources contain no protease-stability assay for SS-31 and no D-Arg versus L-Arg comparison, so this is a design inference rather than a measured structure-activity result. What is documented is that in mice the intact peptide peaked at 1 hour with comparable concentrations in plasma, liver and kidney[5]. Survival in circulation fits a protease-resistant design, but it does not isolate which residue provides the resistance.
Dimethyltyrosine: the Antioxidant Residue

Dmt is tyrosine with methyl groups at the 2′ and 6′ ring positions, flanking the phenolic hydroxyl. The functional claims attached to it are the most direct structure-activity evidence in this set. Peptides of the SS family scavenge hydrogen peroxide and peroxynitrite and inhibit lipid peroxidation, and that antioxidant action is attributed to the tyrosine or dimethyltyrosine residue[4]. When dimethyltyrosine was removed, the analogues no longer inhibited mitochondrial ROS generation or mitochondrial swelling, and failed to prevent myocardial stunning[3]. That comparison — same motif, Dmt deleted, activity lost — is what makes Dmt the residue to watch.
Dmt also contributes to chemical stability. It is described as stabilising the peptide structure by preventing oxidation, adding to the molecule’s overall stability[2]. In the cardiolipin model its aromatic ring inserts into the hydrophobic acyl-chain region alongside phenylalanine, and the peptide’s amphipathic character — hydrophobic Phe and Dmt against hydrophilic D-Arg and Lys — is what lets it interact with both the bilayer and the aqueous phase[1][2].
What Dmt does chemically at the concentrations used is less settled than the deletion result. Cell protection in the reported experiments reached EC50 values in the nanomolar range[3][4], and the read sources do not resolve how a tetrapeptide at those concentrations produces the measured antioxidant effects. One assay points away from direct redox chemistry: SS-31 had no effect on cytochrome c reduction by glutathione or ascorbate, but prevented the inhibition caused by cardiolipin at a 1:1 peptide-to-cardiolipin ratio[1]. In that system the peptide acted on the lipid–protein interface rather than as a reducing agent.
Net Charge, Permeability, and Inner-Membrane Accumulation
A peptide carrying three positive charges should not cross a lipid bilayer easily, yet SS-31 does. Uptake is linear and independent of receptor- or transporter-mediated processes, which is consistent with diffusion[1]. One proposal is that electrons in the pi orbitals of the phenylalanine and dimethyltyrosine rings shield the positive charges enough to allow passage; the review presenting this explanation labels it a suggestion[2].
Inside the cell, the peptide accumulates on the inner mitochondrial membrane rather than in the matrix. Uptake by isolated mitochondria was rapid and independent of mitochondrial potential, and fractionation placed the peptide on the inner membrane[1]. Reported enrichment there exceeds 1000-fold[3][4], with the caveat that these measurements used fluorescent or biotinylated analogues rather than unlabelled peptide in tissue[1]. Binding to cardiolipin is high-affinity in a fluorescence assay using a polarity-sensitive analogue[6], and the interaction is described as occurring at a 1:1 molar ratio, with both electrostatic and hydrophobic contacts[1].
Those binding data support a model in which cardiolipin binding drives partitioning to the inner membrane; they do not establish cardiolipin content as the sole or quantitative determinant of localisation in intact tissue.
What Each Experimental System Shows

Cell culture: in N2A cells, the peptides reduced intracellular ROS and cell death caused by tert-butylhydroperoxide, with EC50 in the nanomolar range[3]. Isolated mitochondria: they decreased mitochondrial ROS production, inhibited the permeability transition and swelling, and prevented calcium-induced cytochrome c release[3]. Lipid and protein biochemistry: cardiolipin binding at 1:1 stoichiometry, and protection of cytochrome c from cardiolipin-induced peroxidase activity[1][6].
Animal work: rats pretreated with SS-31 kept cristae architecture during renal ischaemia, avoided mitochondrial swelling, and recovered ATP quickly on reperfusion[6]. Mouse pharmacokinetics show the peptide distributing to plasma, liver and kidney[5]. These are animal endpoints; they support the mechanism, not a clinical claim.
Human data in this set are limited to regulatory status, not outcomes. A 2013 review noted that SS-31 was in clinical trials for ischaemia-reperfusion injury[6], and elamipretide (SS-31[2]) received accelerated approval from the FDA in September 2025 for Barth syndrome in patients weighing at least 30 kg[7]. An approval for one elamipretide product in one indication says nothing about other uses, and it does not establish the identity, purity or suitability of any research-grade lot.
For the sequence itself, the evidence is uneven: the Dmt deletion result is direct structure-activity evidence, whereas the cardiolipin contacts and the charge-shielding explanation are mechanistic models built from binding, uptake and structural data rather than residue-by-residue tests, and the available sources do not establish which feature dominates in a given tissue.
Related research: What Is SS-31? Cardiolipin and Mitochondrial Function; SS-31 vs MOTS-c: Two Mitochondrial Research Approaches; SS-31.
Research Use Only. SS-31 is discussed as a research material. This article gives no human or veterinary dose, route, schedule, formulation or administration guidance, and no diagnostic or therapeutic recommendation.
References
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol 2014;171:2029–2050
- Tung C, Varzideh F, Farroni E, et al. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. Int J Mol Sci 2025;26:944
- Zhao K, Zhao GM, Wu D, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 2004;279:34682–34690
- Szeto HH. Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J 2006;8:E277–E283
- Wyss JC, Kumar R, Mikulic J, et al. Differential Effects of the Mitochondria-Active Tetrapeptide SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH2) and Its Peptidase-Targeted Prodrugs in Experimental Acute Kidney Injury. Front Pharmacol 2019;10:1209
- Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol 2013;24:1250–1261
- U.S. Food and Drug Administration. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome (19 September 2025)